Vector LifeSciences SA (VLS) is a privately-held SME incorporated in Geneva, Switzerland that is dedicated to the design and development of tissue-selective drugs. VLS's main focus is in oncology, where it uses its platform of proprietary cell penetrating peptides (CPPs) vectors to develop novel antineoplastics and therapeutic vaccines for use in the treatment of cancers with high incidence, high mortality and/or major unmet medical needs.